Have any questions? 706-721-6582 or cts@augusta.edu
- NKTR 16-214-05 (PROPEL) - A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF COMBINED BEMPEGALDESLEUKIN (NKTR-214) AND PEMBROLIZUMAB WITH OR WITHOUT CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Clinical Trial
NKTR 16-214-05 (PROPEL) - A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF COMBINED BEMPEGALDESLEUKIN (NKTR-214) AND PEMBROLIZUMAB WITH OR WITHOUT CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
The purpose of the study is to study how your immune system responds to the investigational drug called bempegaldesleukin (NKTR-214) when it is combined with the FDA approved drug pembrolizumab (KEYTRUDAź) in patients with locally advanced or metastatic solid tumors. The study will investigate the effect of the experimental combination of these study treatments on your tumor(s).
Eligibility Criteria
- Male or female, aged 18 years or older Patients may have received no more than one prior line of systemic therapy for locally advanced or metastatic cancer. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
RESEARCH. INNOVATION. DISCOVERY.